Filing Details
- Accession Number:
- 0001209191-14-008352
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2014-02-07 16:04:00
- Reporting Period:
- 2014-02-05
- Filing Date:
- 2014-02-07
- Accepted Time:
- 2014-02-07 16:04:00
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 875320 | Vertex Pharmaceuticals Inc / Ma | VRTX | Pharmaceutical Preparations (2834) | 043039129 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1453943 | Thomas Connolly | C/O Vertex Pharmaceuticals Incorporated 50 Northern Avenue Boston MA 02210 | Svp, Human Resources | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2014-02-05 | 11,875 | $0.01 | 15,647 | No | 4 | A | Direct | |
| Common Stock | Acquisiton | 2014-02-05 | 938 | $45.11 | 16,585 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2014-02-05 | 200 | $76.82 | 16,385 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2014-02-05 | 738 | $77.83 | 15,647 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | A | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Employee Stock Option (right to buy) | Acquisiton | 2014-02-05 | 62,750 | $0.00 | 62,750 | $77.31 |
| Common Stock | Employee Stock Option (right to buy) | Disposition | 2014-02-05 | 938 | $0.00 | 938 | $45.11 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 62,750 | 2024-02-04 | No | 4 | A | Direct | |
| 11,250 | 2023-02-04 | No | 4 | M | Direct |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock | 150 | Indirect | 401(k) |
Footnotes
- Stock grant under 2006 Stock and Option Plan, vesting on 2/5/2018, subject to (i) acceleration of 50% of shares upon (a) reaching a specified net product sales level over a one-year period for a combination regimen that includes ivacaftor and a CFTR corrector or (b) dosing of the first patient in the first clinical trial to evaluate a second-generation CFTR corrector compound and (ii) acceleration of 50% of shares upon (a) dosing of the first patient in a pivotal trial for a regimen including VX-661 or a specified cancer compound or (b) reaching a specified net product sales level over a one-year period for all our products.
- Transaction made pursuant to Mr. Connolly's company approved trading plan under Rule 10b5-1.
- Open market sales reported on this line occurred at a weighted average price of $76.82 (range $76.49 to $77.14).
- Mr. Connolly undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- Open market sales reported on this line occurred at a weighted average price of $77.83 (range $77.47 to $78.13).
- The option vests in 16 quarterly installments from 02/05/2014.
- The option vests in 16 quarterly installments from 02/05/2013.
Billionaire Hedge Funds
